Starpharma Holdings Limited (FRA:PQ6)

Market Cap	126.01M +399.0%
Revenue (ttm)	8.28M +250.6%
Net Income	-1.84M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	776
Average Volume	39
Open	0.2860
Previous Close	0.2800
Day's Range	0.2860 - 0.2860
52-Week Range	0.0310 - 0.2860
Beta	n/a
RSI	64.68
Earnings Date	Feb 25, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 40
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PQ6

Financial Performance

In fiscal year 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.

Financial numbers in AUD